ストックスクリーナーアプリを入手
14.43
0.14%
0.02
アフターアワーズ：
14.43
前日終値:
$14.41
開ける：
$14.41
24時間の取引高:
2.11M
Relative Volume:
0.21
時価総額：
$4.53B
収益：
$634.21M
当期純損益:
$-27.11M
株価収益率:
-163.05
EPS:
-0.0885
ネットキャッシュフロー:
$29.85M
1週間 パフォーマンス:
+0.42%
1か月 パフォーマンス:
+0.63%
6か月 パフォーマンス:
+73.44%
1年 パフォーマンス:
+67.40%
1日の値動き範囲:
$14.40
$14.43
1週間の範囲:
$14.37
$14.43
52週間の値動き範囲:
$5.51
$14.43
Amicus Therapeutics Inc Stock (FOLD) Company Profile
名前
Amicus Therapeutics Inc
セクター
電話
(609) 662-2000
住所
47 HULFISH STREET, PRINCETON, NJ
Compare FOLD vs VRTX, REGN, ALNY, ARGX, INSM
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
FOLD
Amicus Therapeutics Inc
|
14.43 | 4.52B | 634.21M | -27.11M | 29.85M | -0.0885 |
VRTX
Vertex Pharmaceuticals Inc
|
454.97 | 113.96B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
749.47 | 78.41B | 14.34B | 4.50B | 3.77B | 41.56 |
ALNY
Alnylam Pharmaceuticals Inc
|
328.70 | 40.85B | 3.71B | 313.75M | 465.38M | 2.2571 |
ARGX
Argen X Se Adr
|
697.05 | 42.05B | 4.16B | 1.29B | 734.26M | 19.58 |
INSM
Insmed Inc
|
148.31 | 29.99B | 606.42M | -1.28B | -997.58M | -6.403 |
Amicus Therapeutics Inc Stock (FOLD) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-01-22 | ダウングレード | Jefferies | Buy → Hold |
| 2025-12-29 | ダウングレード | Leerink Partners | Outperform → Market Perform |
| 2025-12-22 | ダウングレード | TD Cowen | Buy → Hold |
| 2025-12-17 | 開始されました | Citigroup | Buy |
| 2025-09-18 | アップグレード | Needham | Hold → Buy |
| 2025-07-17 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2024-12-13 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2024-09-06 | 開始されました | Jefferies | Buy |
| 2024-05-30 | 開始されました | Wells Fargo | Overweight |
| 2024-05-14 | アップグレード | Guggenheim | Neutral → Buy |
| 2023-12-19 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2022-09-09 | 開始されました | Morgan Stanley | Equal-Weight |
| 2022-04-13 | 再開されました | Goldman | Neutral |
| 2022-01-14 | アップグレード | SVB Leerink | Mkt Perform → Outperform |
| 2021-11-15 | アップグレード | Stifel | Hold → Buy |
| 2021-09-30 | アップグレード | JP Morgan | Neutral → Overweight |
| 2021-07-19 | 再開されました | BTIG Research | Buy |
| 2021-05-27 | 開始されました | Needham | Hold |
| 2021-05-21 | 開始されました | UBS | Buy |
| 2021-04-14 | アップグレード | Cantor Fitzgerald | Neutral → Overweight |
| 2021-03-02 | 開始されました | Stifel | Hold |
| 2021-02-12 | ダウングレード | Cantor Fitzgerald | Overweight → Neutral |
| 2021-02-12 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2020-12-28 | 再開されました | Cantor Fitzgerald | Overweight |
| 2020-12-10 | ダウングレード | Citigroup | Buy → Neutral |
| 2020-11-11 | 開始されました | Berenberg | Hold |
| 2020-06-17 | 開始されました | BTIG Research | Buy |
| 2020-02-04 | 再開されました | Cantor Fitzgerald | Overweight |
| 2019-11-12 | 繰り返されました | H.C. Wainwright | Buy |
| 2019-06-17 | 開始されました | H.C. Wainwright | Buy |
| 2019-06-05 | 繰り返されました | Cantor Fitzgerald | Overweight |
| 2019-04-05 | 開始されました | Janney | Buy |
| 2019-01-30 | 開始されました | Cantor Fitzgerald | Overweight |
| 2018-10-29 | 開始されました | Citigroup | Neutral |
| 2018-08-17 | ダウングレード | Chardan Capital Markets | Buy → Neutral |
| 2017-10-06 | 再開されました | Goldman | Neutral |
| 2017-09-13 | 繰り返されました | Chardan Capital Markets | Buy |
| 2017-08-10 | 繰り返されました | Chardan Capital Markets | Buy |
| 2017-01-24 | アップグレード | Robert W. Baird | Neutral → Outperform |
| 2016-05-18 | 開始されました | BofA/Merrill | Buy |
| 2016-04-14 | 開始されました | Robert W. Baird | Neutral |
| 2016-04-12 | 繰り返されました | Chardan Capital Markets | Buy |
| 2015-09-16 | ダウングレード | Chardan Capital Markets | Buy → Neutral |
| 2015-06-16 | 繰り返されました | Chardan Capital Markets | Buy |
すべてを表示
Amicus Therapeutics Inc (FOLD) 最新ニュース
Morgan Stanley Upgrades Amicus (FOLD) on IP Strength and Pipeline Expansion - MSN
Amicus Therapeutics (NASDAQ:FOLD) Hits New 52-Week HighWhat's Next? - MarketBeat
Amicus Therapeutics stock hits 52-week high at 14.39 USD - Investing.com
Amicus Therapeutics stock hits 52-week high at 14.39 USD By Investing.com - Investing.com South Africa
Hudson Bay Capital Management LP Cuts Position in Amicus Therapeutics, Inc. $FOLD - MarketBeat
Amicus Therapeutics, Inc.(NasdaqGM: FOLD) dropped from NASDAQ Biotechnology Index - marketscreener.com
FOLD Should I Buy - Intellectia AI
872,411 Shares in Amicus Therapeutics, Inc. $FOLD Acquired by Ion Asset Management Ltd. - MarketBeat
Iron Triangle Partners LP Takes Position in Amicus Therapeutics, Inc. $FOLD - MarketBeat
BioMarin to acquire rare disease drug developer Amicus for $4.8B - MSN
Amicus Therapeutics, Inc. (NASDAQ:FOLD) Receives Consensus Recommendation of "Hold" from Analysts - MarketBeat
Assessing Amicus Therapeutics (FOLD) Valuation After Recent Share Price Momentum And DCF Upside - Yahoo Finance
Amicus Therapeutics stock hits 52-week high at 14.38 USD By Investing.com - Investing.com Nigeria
Elevation Point Wealth Partners LLC Makes New Investment in Amicus Therapeutics, Inc. $FOLD - MarketBeat
Assessing Amicus Therapeutics (FOLD) Valuation After Strong Recent Share Price Momentum - simplywall.st
Amicus Therapeutics, Inc. $FOLD Shares Sold by Prosight Management LP - MarketBeat
Avoro Capital Advisors LLC Decreases Stock Holdings in Amicus Therapeutics, Inc. $FOLD - MarketBeat
Assessing Amicus Therapeutics (FOLD) After Strong One Year Share Price Performance - simplywall.st
Amicus Therapeutics stock hits 52-week high at 14.38 USD - Investing.com India
Amicus Therapeutics (NASDAQ:FOLD) Reaches New 12-Month HighTime to Buy? - MarketBeat
Genomenon and Amicus Therapeutics Partner to Advance Fabry Disease Awareness and Diagnosis - PR Newswire
Amicus Therapeutics (FOLD) Announces Approval for Pombiliti + Opfolda by Japan’s Ministry of Health, Labour and Welfare (MHLW) - MSN
Jefferies Downgrades Amicus Therapeutics, Inc. (FOLD) to Buy And Lowers Price Target Amid Takeover Developments - MSN
How The Amicus Therapeutics (FOLD) Story Is Shifting Inside BioMarin’s Rare Disease Portfolio - Yahoo Finance
Amicus Therapeutics2026 Funding Rounds & List of Investors - Tracxn
Amicus Therapeutics Buyout Advances As Valuation Gap Draws Investor Focus - Yahoo Finance
Bradley Campbell Sells 22,500 Shares of Amicus Therapeutics (NASDAQ:FOLD) Stock - MarketBeat
Insider Sell: Bradley Campbell Sells 22,500 Shares of Amicus The - GuruFocus
Amicus Therapeutics (FOLD) CEO Bradley Campbell sells 22,500 shares in open market - Stock Titan
FOLD SEC FilingsAmicus Therapeut 10-K, 10-Q, 8-K Forms - Stock Titan
FDA’s rare disease toolbox not fully used - BioWorld MedTech
JPMorgan Chase & Co. Has $16.68 Million Stock Position in Amicus Therapeutics, Inc. $FOLD - MarketBeat
Is It Too Late To Consider Amicus Therapeutics (FOLD) After The Proposed BioMarin Deal Price? - simplywall.st
Amicus Therapeutics shareholders approve acquisition by BioMarin Pharmaceutical - Investing.com
Amicus Stockholders Approve BioMarin Acquisition at Special Meeting - TipRanks
Shareholders back Amicus (NASDAQ: FOLD) sale to BioMarin Pharmaceutical - Stock Titan
Amicus Therapeutics, Inc. (FOLD) Stock Analysis: Navigating the Biotech Sector with a 23.7% Revenue Growth - DirectorsTalk Interviews
Bradley Campbell sells 75,000 FOLD shares under 10b5-1 plan (FOLD) - Stock Titan
Vanguard Group Inc. Buys 126,441 Shares of Amicus Therapeutics, Inc. $FOLD - MarketBeat
William Blair Investment Management LLC Buys 1,107,083 Shares of Amicus Therapeutics, Inc. $FOLD - MarketBeat
Fox Run Management L.L.C. Takes $553,000 Position in Amicus Therapeutics, Inc. $FOLD - MarketBeat
Primecap Management Co. CA Sells 128,200 Shares of Amicus Therapeutics, Inc. $FOLD - MarketBeat
FOLD Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
Amicus Therapeutics Experiences Revision in Stock Score Amid Mixed Financial Performance - Markets Mojo
BIOMARIN PHARMACEUTICAL INC SEC 10-K Report - TradingView
BioMarin Deal Reshapes Amicus Therapeutics Outlook For Growth And Portfolio - simplywall.st
Amicus Therapeutics, Inc. (FOLD) Stock Analysis: Navigating Growth in Rare Diseases with Strong Revenue Momentum - DirectorsTalk Interviews
BioMarin Amicus Deal Shifts Rare Disease Portfolio And Valuation Focus - Yahoo Finance
Precision Trading with Amicus Therapeutics Inc. (FOLD) Risk Zones - Stock Traders Daily
BioMarin Reports Fourth Quarter and Full-year 2025 Financial and Operating Results - The AI Journal
Amicus' Q4 Earnings Miss, Higher Product Sales Drive Y/Y Revenues - Finviz
Amicus Therapeutics Inc (FOLD) 財務データ
収益
当期純利益
現金流量
EPS
1.82%
大文字化:
|
ボリューム (24 時間):